CAR-T

#CAR-T #Cell and gene therapy #Cell therapy #Gene therapy

This week in drug discovery (9-13 December) 

News round-up for 9-13 December by DDW Senior Digital Content Editor Diana Spencer. It’s been a big week for cell and gene therapies (CGTs) as the first in vivo BCMA CAR-T candidate reaches the clinic and a new discovery could lead to a gene therapy that reverses a… Read More

#News

Cancer cells
#Cancer research #CAR-T #Gene mutation #Genetics / genomics #Immunotherapy #Interview #Mass spectrometry / NMR #Meet the Researcher #Nautilus #Oncology #Precision medicine #Protein chemistry / Proteomics #Rare cancers

Podcast: New ways of looking at effective cancer treatment

This is the latest episode of the free DDW narrated podcast, titled “New ways of looking at effective cancer treatment”, which covers three articles written for DDW Volume 24 – Issue 2, Spring 2023 of DDW. They are called: “3D Genomics and targeted cancer therapies”, “Democratising… Read More

#News

Blood cancer
#Blood cancer #CAR-T #Cell therapy #Haematology #Oncology #Phase I trial #Synthekine

Positive initial results from trial of CD19 CAR-T in blood cancers

Synthekine has announced positive initial results from a Phase I study of SYNCAR-001 + STK-009 for the treatment of relapsed or refractory CD19+ haematologic malignancies.  In the results presented from eight patients treated in the dose escalation portion of the study with a fixed SYNCAR-001 infusion of… Read More

#Cancer Research #News

CAR-T therapy
#CAR-T #Cell therapy #EsoBiotec #In vivo #Myeloma #Phase I trial

First in vivo BCMA CAR-T candidate reaches the clinic

A clinical trial has launched in China of ESO-T01, an immune shielded lentiviral vector that reprograms T lymphocytes in vivo into BCMA CAR-T cells, for the treatment of multiple myeloma.  The proof-of-concept, first-in-human trial is underway and initial clinical data are expected to be presented… Read More

#Editor's Choice #News

#Artificial intelligence (AI) #CAR-T #Drug discovery #Exosomes #Oncology #Weight loss

New DDW Highlights podcast: 9 December 2024

The latest episode of the DDW Highlights podcast is now available to listen to and watch below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates. This week’s leading news stories all shine a light on… Read More

#News

#Artificial intelligence (AI) #CAR-T #Drug discovery #Exosomes #Oncology #Weight loss

This week in drug discovery (2-6 December) 

News round-up for 2-6 December by DDW Senior Digital Content Editor Diana Spencer. This week’s leading news stories all shine a light on innovation within drug discovery, including a potential ‘best-in-industry’ weight loss drug, a gold-based compound that shrinks tumours by 82%, and a second-generation CAR-T therapy. Read More

#News

CAR-T cells attacking a cancer cell
#CAR-T #Cell therapy #High throughput screening #Live cell analysis #Oncology #Webinar

Last chance: Optimising expansion conditions for CAR-T cells

The development of gene-modified cell therapies, particularly CAR-T cells, has transformed cancer treatment by offering personalised and potentially curative options. But how can you enhance the characterisation and expansion of CAR-T cells and address ‘on target, off tumour’ effects? Register now for this exclusive… Read More

Webinar date:
Supported by Sartorius
#News

CAR-T cells attack cancer cells
#Autolus #Blood cancer #CAR-T #Cell therapy #Leukaemia #Oncology #University College London

Next-generation therapy overcomes limitations of other CAR-T

A new chimeric antigen receptor T cell (CAR-T) therapy has delivered highly promising results in treating patients with relapsed/refractory B-cell acute lymphoblastic leukaemia (r/r B-ALL).  The FELIX clinical trial was led by researchers at University College London (UCL) and UCLH and sponsored by UCL spin-out Autolus Therapeutics. Read More

#Cancer Research #Editor's Choice #News

Roche headquarters
#CAR-T #Cell therapy #Mergers and acquisitions #Poseida Therapeutics #Roche

Roche buys CAR-T specialist Poseida Therapeutics for $1.5bn

Roche has entered into a definitive merger agreement to acquire Poseida Therapeutics, a public clinical-stage biopharmaceutical company pioneering donor-derived CAR-T cell therapies.  Roche will acquire the company for $9 per share in cash at closing, representing a total equity value of approximately $1 billion.  Stockholders would also receive a non-tradeable contingent… Read More

#Business & Investment #News #Trending News

CAR-T therapy
#CAR-T #Cell therapy #High throughput screening #Live cell analysis #Oncology #Webinar

Register now: Learn techniques for optimising CAR-T expansion

The development of gene-modified cell therapies, particularly CAR-T cells, has transformed cancer treatment by offering personalised and potentially curative options. But how can you enhance the characterisation and expansion of CAR-T cells and address ‘on target, off tumour’ effects? Register now for this exclusive… Read More

Webinar date:
Supported by Sartorius
#News

CAR-T therapy
#CAR-T #Cell therapy #High throughput screening #Live cell analysis #Oncology #Webinar

Characterise CAR-T cells: Address ‘on target, off tumour’ effects

The development of gene-modified cell therapies, particularly CAR-T cells, has transformed cancer treatment by offering personalised and potentially curative options. But how can you enhance the characterisation and expansion of CAR-T cells and address ‘on target, off tumour’ effects? Register now for this exclusive… Read More

Webinar date:
Supported by Sartorius
#News

CAR-T therapy
#Autoimmune disease #CAR-T #Kyverna Therapeutics #Lupus

CAR-T therapy for lupus nephritis “resets the immune system”

Kyverna Therapeutics has revealed plans to present updated clinical data from lupus nephritis (LN) patients treated with KYV-101 at the American College of Rheumatology (ACR) Covergence 2024. The data are from the ongoing Kyverna-sponsored KYSA-1 and KYSA-3 Phase I/II studies and named patient treatments. Read More

#News #Trending News

CAR-T therapy for leukaemia
#Autolus #CAR-T #Cell therapy #FDA #Immunotherapy #Leukaemia #Oncology

First FDA approval for new CAR-T therapy

The US Food and Drug Administration (FDA) has approved Autolus’ obecabtagene autoleucel (Aucatzyl), a CD19-directed genetically modified autologous T cell immunotherapy, for adults with relapsed or refractory B-cell precursor acute lymphoblastic leukaemia (ALL). The efficacy of obecabtagene autoleucel was evaluated in FELIX, an open-label, multicentre, single-arm trial that enrolled adults… Read More

#News #Regulatory #Trending News

CAR-T cells attacking a cancer cell
#CAR-T #Cell therapy #High throughput screening #Live cell analysis #Oncology #Webinar

Webinar: Enhance the characterisation of CAR-T cells

The development of gene-modified cell therapies, particularly CAR-T cells, has transformed cancer treatment by offering personalised and potentially curative options. But how can you enhance the characterisation and expansion of CAR-T cells and address ‘on target, off tumour’ effects? Register now for this exclusive… Read More

Webinar date:
Supported by Sartorius
#News

CAR-T cell therapy
#CAR-T #Cell therapy #Financing #Fundraising #Haematology #March Biosciences #Oncology

March Bio raises $28.4m for autologous CAR-T therapy

Biotechnology company March Biosciences (March Bio) has announced the close of a $28.4 million oversubscribed Series A financing, having raised over $51 million to date. Mission BioCapital and 4BIO Capital led the financing, with participation from KdT Ventures, Alexandria Venture Investments, Volnay Therapeutics, Modi Ventures, and Mansueto Investments. Existing investors… Read More

#Business & Investment #News

CAR-T therapy
#CAR-T #Investment #Oncology

AvenCell raises $112 million for switchable CAR-T cell therapies 

AvenCell Therapeutics has raised $112 million in Series B financing to support the development of both autologous and allogeneic switchable CAR-T cell therapies.   The financing was led by global life sciences investor Novo Holdings. New investors F-Prime Capital, Eight Roads Ventures Japan, Piper Heartland Healthcare Capital and NYBC Ventures also… Read More

#Business & Investment #News